Targeting Neuroinflammation as a Contributing Pathology in Alzheimer’s Disease Dementia


About this study

The purposes of this study are to determine if neuroinflammation, as measured by PET imaging, is associated with Ab plaques in cognitively impaired vs. cognitively unimpaired participants, to determine if neuroinflammation, as measured by neuroinflammation PET imaging, is associated with the rate of cognitive in the 5 years preceding PET imaging, and to determine if neuroinflammation, as measured by PET imaging, is associated with plasma biomarkers of inflammation.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Males or females 60 years of age or older.
  • Meet the requirements for one of the four groups (CU A−, CU A+, MCI A+, AD A+).
  • Neurologic evaluation procedures with testing in the MCSA or ADRC or Mayo Clinic Behavioral Neurology Practice. Must have had or plan to have at least 2 testing sessions.
  • All participants must complete an amyloid PiB PET scan and MRI brain scan within approximately 6 months prior to the ER176 PET/CT scan.
  • Capacity to sign consent or have a legally authorized representative to sign the consent.

Exclusion Criteria:

  • Participants unable to lie down without moving for 20 minutes.
  • Women who are pregnant or cannot stop breast feeding for 24 hours.
  • Actively taking daily anti-inflammatory medications (NSAIDs, corticosteroids, etc.) except for a small control group. Anti-inflammatory creams, eye drops, and nasal sprays are not exclusions.
  • Generalized inflammatory condition and treatment with immunosuppressive, corticoid/glucocorticoid, steroidal or non-steroidal anti-inflammatory medication within 2 weeks of scanning (only acute medication use as an exclusion so as to limit medication interaction but preserve possible chronic systemic inflammation interaction).
  • Standard safety exclusionary criteria for MRI such as metallic foreign bodies, pacemaker, etc., since the quantitative PET data analysis is based on anatomic criteria that are established uniquely for each subject by registration to his/her MRI.

Eligibility last updated 8/20/21. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Val Lowe, M.D.

Closed-enrolling by invitation

What is this? (?)
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Jessica Brunn

(507) 422-6025

More information


Publications are currently not available